Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 188 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ctDNA Clear all
Active, not recruiting No phase listed Observational

Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery

NCT05914792
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
70 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting No phase listed Observational

Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

NCT05081024
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT07136077
View directory record Official record
Conditions
Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Tislelizumab, ctDNA
Interventions
Tislelizumab, Fruquintinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

NCT07504796
View directory record Official record
Conditions
Metastatic Melanoma, Advanced Melanoma
Interventions
Nivolumab, Relatlimab, Ipilimumab, Signatera genome MRD assay
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

NCT02955758
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Interventions
Pembrolizumab
Biological
Lead sponsor
Joel Neal
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 28, 2026, 4:48 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

NCT05127096
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
FirstSight blood test
Diagnostic Test
Lead sponsor
CellMax Life
Industry
Eligibility
45 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
15
States / cities
Huntsville, Alabama • Chula Vista, California • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 28, 2026, 4:48 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Niraparib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Burbank, California • Duarte, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 28, 2026, 4:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease

NCT02612350
View directory record Official record
Conditions
Mutation, Neoplasms
Interventions
ctDNA Analysis for the Detection of Genetic Mutations
Genetic
Lead sponsor
Pathway Genomics
Industry
Eligibility
18 Years and older
Enrollment
1,106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 28, 2026, 4:48 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

NCT04136002
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
45 Years to 84 Years
Enrollment
44,467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
271
States / cities
Anniston, Alabama • Guntersville, Alabama • Huntsville, Alabama + 217 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Terminated No phase listed Observational

Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

NCT03594448
View directory record Official record
Conditions
Microsatellite Instability, Colorectal Cancer Stage IV
Interventions
Specimen Collection, Serial Liquid Biopsy
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 28, 2026, 4:48 AM EDT
Completed No phase listed Observational

Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

NCT05945290
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma, Locally Advanced Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

NCT06518837
View directory record Official record
Conditions
Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Smartphone-enabled Hybrid Identification of Early CoLorectal Disease Using Blood-Based Cancer Testing Across TeXas

NCT07398456
View directory record Official record
Conditions
Colorectal Cancer (CRC) Screening
Interventions
Educational Information via Smartphone App
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
45 Years to 84 Years
Enrollment
5,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting No phase listed Observational

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

NCT06606028
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

NCT06716580
View directory record Official record
Conditions
Lung Cancer, EGFR Gene Mutation
Interventions
Circulating Tumor DNA (ctDNA) Assay
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
40 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
6
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting No phase listed Observational

Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

NCT02586389
View directory record Official record
Conditions
Non-hematologic Cancer
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Active, not recruiting Phase 2 Interventional

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT05343013
View directory record Official record
Conditions
Colorectal Cancer
Interventions
TAS-102
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting Phase 3 Interventional

Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

NCT04585490
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
Interventions
Durvalumab, Carboplatin, Pemetrexed, Paclitaxel, Cisplatin, AVENIO ctDNA Surveillance Kit, Tremelimumab
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Completed No phase listed Observational

Concordance Between ctDNA Assay and FoundationOne

NCT02620527
View directory record Official record
Conditions
Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing, Genomic Alterations
Interventions
Not listed
Lead sponsor
Foundation Medicine
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting Phase 1 Interventional

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

NCT06005324
View directory record Official record
Conditions
HPV-Negative Squamous Cell Carcinoma
Interventions
Paclitaxel, Carboplatin, Cetuximab, Standard Dose Radiation, Low Dose Radiation, Cisplatin, TFHX Regimen
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 28, 2026, 4:48 AM EDT
Active, not recruiting No phase listed Observational

Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer

NCT04308720
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Active, not recruiting Early Phase 1 Interventional

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

NCT05333874
View directory record Official record
Conditions
Breast Cancer, Early-Onset
Interventions
Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

NCT04768426
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Cancer
Interventions
Capecitabine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 4:48 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

NCT07025785
View directory record Official record
Conditions
Breast Cancer, Lymph Node Metastasis
Interventions
Circulating tumor DNA
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 4:48 AM EDT